Business Context and Reporting Period
This Form 8-K is a current report filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on September 27, 2024. The filing addresses corporate governance matters regarding the scheduling of the company's 2024 Annual Meeting of Stockholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on procedural updates regarding shareholder meetings and does not contain financial performance data.
Material Changes
The primary material change reported is the rescheduling of the 2024 Annual Meeting of Stockholders. The Board of Directors established December 20, 2024, as the new meeting date. This represents a change of more than 30 days from the anniversary of the previous annual meeting, triggering specific disclosure requirements under Rule 14a-5(f) of the Exchange Act.
Guidance, Outlook, and Management Commentary
Management has not provided financial guidance or operational outlook in this filing. The document details new deadlines for stockholder actions:
- Record Date: Stockholders of record as of the close of business on October 25, 2024, are entitled to vote.
- Proposal Deadline (Rule 14a-8): Written notice for proposals to be included in proxy materials must be received by October 7, 2024.
- Advance Notice Deadline: Proposals for business outside Rule 14a-8 or director nominations must be delivered by October 7, 2024.
- Universal Proxy Notice: Stockholders intending to solicit proxies for director nominees other than the Company's must provide notice by October 21, 2024.
Important Facts for Investors to Verify
- Verify the correct registrant name is Salarius Pharmaceuticals, Inc. (Ticker: SLRX), as the input metadata referenced Decoy Therapeutics Inc.
- Confirm the new Annual Meeting date of December 20, 2024, and note that specific time and location details will be in a future proxy statement.
- Check the October 25, 2024 record date to determine voting eligibility.
- Review the strict deadlines of October 7, 2024 and October 21, 2024 for submitting shareholder proposals or director nominations.